Fig. 4.
Fig. 4. (A) EMSA assay of wild-type (W-EtsP, lanes 1-8) and mutant (W-▵EtsP, lanes 9-10) oligonucleotides for the WASP proximal Ets binding site with Jurkat nuclear extracts: labeled oligonucleotide was incubated with Jurkat nuclear extracts as detailed in Materials and Methods and competed with a 50-fold molar excess of the competitors indicated. (B) EMSA assay of wild-type (W-EtsD, lanes 1-8) and mutant (W-▵EtsD, lanes 9-10) oligonucleotides for the WASP distal Ets binding site with Jurkat nuclear extracts: labeled oligonucleotide was incubated with Jurkat nuclear extracts as detailed in Materials and Methods and competed with a 50-fold molar excess of the competitors indicated.

(A) EMSA assay of wild-type (W-EtsP, lanes 1-8) and mutant (W-▵EtsP, lanes 9-10) oligonucleotides for the WASP proximal Ets binding site with Jurkat nuclear extracts: labeled oligonucleotide was incubated with Jurkat nuclear extracts as detailed in Materials and Methods and competed with a 50-fold molar excess of the competitors indicated. (B) EMSA assay of wild-type (W-EtsD, lanes 1-8) and mutant (W-▵EtsD, lanes 9-10) oligonucleotides for the WASP distal Ets binding site with Jurkat nuclear extracts: labeled oligonucleotide was incubated with Jurkat nuclear extracts as detailed in Materials and Methods and competed with a 50-fold molar excess of the competitors indicated.

Close Modal

or Create an Account

Close Modal
Close Modal